Literature DB >> 25774714

Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.

Matthias Obenaus1, Catarina Leitão1, Matthias Leisegang1, Xiaojing Chen1, Ioannis Gavvovidis1, Pierre van der Bruggen2, Wolfgang Uckert3, Dolores J Schendel4, Thomas Blankenstein5.   

Abstract

Identifying T-cell receptors (TCRs) that bind tumor-associated antigens (TAAs) with optimal affinity is a key bottleneck in the development of adoptive T-cell therapy of cancer. TAAs are unmutated self proteins, and T cells bearing high-affinity TCRs specific for such antigens are commonly deleted in the thymus. To identify optimal-affinity TCRs, we generated antigen-negative humanized mice with a diverse human TCR repertoire restricted to the human leukocyte antigen (HLA) A*02:01 (ref. 3). These mice were immunized with human TAAs, for which they are not tolerant, allowing induction of CD8⁺ T cells with optimal-affinity TCRs. We isolate TCRs specific for the cancer/testis (CT) antigen MAGE-A1 (ref. 4) and show that two of them have an anti-tumor effect in vivo. By comparison, human-derived TCRs have lower affinity and do not mediate substantial therapeutic effects. We also identify optimal-affinity TCRs specific for the CT antigen NY-ESO. Our humanized mouse model provides a useful tool for the generation of optimal-affinity TCRs for T-cell therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25774714     DOI: 10.1038/nbt.3147

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  46 in total

1.  TCRs with high affinity for foreign pMHC show self-reactivity.

Authors:  Phillip D Holler; Lukasz K Chlewicki; David M Kranz
Journal:  Nat Immunol       Date:  2002-12-09       Impact factor: 25.606

2.  Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.

Authors:  Daphné A Schmid; Melita B Irving; Vilmos Posevitz; Michael Hebeisen; Anita Posevitz-Fejfar; J-C Floyd Sarria; Raquel Gomez-Eerland; Margot Thome; Ton N M Schumacher; Pedro Romero; Daniel E Speiser; Vincent Zoete; Olivier Michielin; Nathalie Rufer
Journal:  J Immunol       Date:  2010-03-29       Impact factor: 5.422

Review 3.  Antigen choice in adoptive T-cell therapy of cancer.

Authors:  Rienk Offringa
Journal:  Curr Opin Immunol       Date:  2009-03-16       Impact factor: 7.486

4.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

5.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

6.  Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette.

Authors:  Matthias Leisegang; Boris Engels; Peter Meyerhuber; Elisa Kieback; Daniel Sommermeyer; Shao-An Xue; Simone Reuss; Hans Stauss; Wolfgang Uckert
Journal:  J Mol Med (Berl)       Date:  2008-03-12       Impact factor: 4.599

7.  MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.

Authors:  J F Toso; C Oei; F Oshidari; J Tartaglia; E Paoletti; H K Lyerly; S Talib; K J Weinhold
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

8.  Production of stable cytolytic T-cell clones directed against autologous human melanoma.

Authors:  M Hérin; C Lemoine; P Weynants; F Vessière; A Van Pel; A Knuth; R Devos; T Boon
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

9.  Coordinated expression of clustered cancer/testis genes encoded in a large inverted repeat DNA structure.

Authors:  Anne Bredenbeck; Verena M Hollstein; Uwe Trefzer; Wolfram Sterry; Peter Walden; Florian O Losch
Journal:  Gene       Date:  2008-02-29       Impact factor: 3.688

10.  NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

Authors:  Daniel Sommermeyer; Heinke Conrad; Holger Krönig; Haike Gelfort; Helga Bernhard; Wolfgang Uckert
Journal:  Int J Cancer       Date:  2012-09-14       Impact factor: 7.396

View more
  39 in total

Review 1.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

Review 2.  Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Katherine E Lindblad; Marina Ruiz de Galarreta; Amaia Lujambio
Journal:  Clin Cancer Res       Date:  2020-04-23       Impact factor: 12.531

3.  Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.

Authors:  Lucia Poncette; Xiaojing Chen; Felix Km Lorenz; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

4.  High-affinity T cell receptors for adoptive cell transfer.

Authors:  Ariel Isser; Jonathan P Schneck
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

5.  Receptor combinations hone T-cell therapy.

Authors:  Thomas Blankenstein
Journal:  Nat Biotechnol       Date:  2016-04       Impact factor: 54.908

6.  Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.

Authors:  Laura T Morton; Rogier M Reijmers; Anne K Wouters; Christiaan Kweekel; Dennis F G Remst; Cilia R Pothast; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Mol Ther       Date:  2019-10-04       Impact factor: 11.454

Review 7.  Enhancing adoptive T cell immunotherapy with microRNA therapeutics.

Authors:  Yun Ji; James D Hocker; Luca Gattinoni
Journal:  Semin Immunol       Date:  2015-12-20       Impact factor: 11.130

8.  Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.

Authors:  Ioannis Gavvovidis; Matthias Leisegang; Gerald Willimsky; Natalie Miller; Paul Nghiem; Thomas Blankenstein
Journal:  Clin Cancer Res       Date:  2018-04-18       Impact factor: 12.531

Review 9.  Current tools for predicting cancer-specific T cell immunity.

Authors:  David Gfeller; Michal Bassani-Sternberg; Julien Schmidt; Immanuel F Luescher
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

Review 10.  Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.

Authors:  Ronnie H Fang; Ashley V Kroll; Liangfang Zhang
Journal:  Small       Date:  2015-09-02       Impact factor: 13.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.